Doxorubicin News and Research

RSS
Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
New study compares chemotherapy drugs with development of cardiomyopathy

New study compares chemotherapy drugs with development of cardiomyopathy

Preparation, characterization of Soyasapogenol B loaded onto functionalized MWCNTs

Preparation, characterization of Soyasapogenol B loaded onto functionalized MWCNTs

Study uncovers how tumors backfire on neoadjuvant chemotherapy

Study uncovers how tumors backfire on neoadjuvant chemotherapy

Soyasapogenol B: A new drug delivery technology for therapeutics

Soyasapogenol B: A new drug delivery technology for therapeutics

New nanoscale technique developed to get more information from the blood of cancer patients

New nanoscale technique developed to get more information from the blood of cancer patients

Using Pre-Clinical Imaging to Detect Cancer

Using Pre-Clinical Imaging to Detect Cancer

Novel DNA nanoplatform delivers anticancer agents to multidrug-resistant tumors

Novel DNA nanoplatform delivers anticancer agents to multidrug-resistant tumors

Mannose - nutritional supplement, could slow some cancers

Mannose - nutritional supplement, could slow some cancers

Nutritional supplement can slow cancer growth and enhance effects of chemotherapy

Nutritional supplement can slow cancer growth and enhance effects of chemotherapy

Sugar supplement shown to slow tumor growth and enhance chemotherapy

Sugar supplement shown to slow tumor growth and enhance chemotherapy

CDK2 protein plays key role in heart damage caused by doxorubicin, finds study

CDK2 protein plays key role in heart damage caused by doxorubicin, finds study

Promising potential of stimuli-responsive nanomaterial for cancer therapy

Promising potential of stimuli-responsive nanomaterial for cancer therapy

SLU researcher seeks to find solutions for 'chemo brain' symptoms and side effects of opioids

SLU researcher seeks to find solutions for 'chemo brain' symptoms and side effects of opioids

Study: Sarcoma patients poorly informed about risk of interactions with anti-cancer drugs

Study: Sarcoma patients poorly informed about risk of interactions with anti-cancer drugs

Study: Chemotherapy drugs may promote muscle mitochondrial dysfunction

Study: Chemotherapy drugs may promote muscle mitochondrial dysfunction

Combination approach appears to improve chemotherapy response, boost anti-tumor immunity

Combination approach appears to improve chemotherapy response, boost anti-tumor immunity

Nanoparticles show promise in treatment for triple-negative breast cancer, finds study

Nanoparticles show promise in treatment for triple-negative breast cancer, finds study

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Immune checkpoint inhibition may be effective in treating HIV-associated Kaposi's sarcoma

Immune checkpoint inhibition may be effective in treating HIV-associated Kaposi's sarcoma